2015 American Transplant Congress
Non-Cytoreductive Immunosuppression Prevents Rejection of Vascularized Composite Allografts
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss such as an extremity or face. Immunosuppression-free donor-specific immunological tolerance has been successfully…2015 American Transplant Congress
Belatacept Based Immunosuppression and Incidence of Proteinuria in Kidney Transplant Recipients
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Abatacept which is a co-stimulation inhibitor has been suggested to have B7-1 mediated antiproteinuric effects. Belatacept which is another co-stimulation agent has been approved…2015 American Transplant Congress
Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy
1University of Maryland School of Medicine, Baltimore; 2Johns Hopkins University, Baltimore.
Belatacept provides immunosuppression via costimulation blockade and has been associated with improved renal function compared to calcineurin inhibitor based therapies. We developed the Maryland Aggregate…2015 American Transplant Congress
Virus Induced CD28 Down-Regulation as a Potential Driver of Costimulation Blockade Resistant Rejection
1Surgery, Emory University, Atlanta, GA; 2Surgery, Duke University, Durham, NC.
Belatacept, a B7-specific fusion protein, blocks CD28-B7 costimulation and prevents kidney allograft rejection. However, it is ineffective in a sizable minority of patients. Although T…2015 American Transplant Congress
Costimulation Blockade Prevents Rejection of Vascularized Composite Allografts
[Background] Vascularized composite allotransplantation (VCA) is an emerging new era in transplant medicine and has become a valid therapeutic option after devastating tissue loss. The…2015 American Transplant Congress
Eomes-Expressing CD8+ T Cells and Th17 Cells Mediate Costimulatory Blockade-Resistant Allograft Rejection in Mice
The etiology of costimulatory blockade-resistant allograft rejection remains unclear. Therefore, the purpose of this study was to evaluate the responsiveness of distinct CD4+ and CD8+…2015 American Transplant Congress
Tissue Engineering Human Kidneys for Costimulation Blockade
1BREONICS, Inc., Watervliet, NY; 2Surgery, University of Utrecht, Utrecht, Netherlands.
Methods for preserving organs have employed hypothermic conditions. At these temperatures metabolism is 4% of normal. Tissue engineering of organs cannot be done without significant…2015 American Transplant Congress
Defining the Role of CD57+CD4 T Cells in Belatacept-Resistant Rejection
1Duke University, Durham, NC; 2Emory University, Atlanta, GA; 3Bristol-Myers Squibb, Princeton, NJ.
Purpose: We have shown that CD57+PD1- CD4 T cells are present in higher numbers in the peripheral blood and allograft biopsies of patients who experienced…2015 American Transplant Congress
Combined Anti-IL6R and CTLA4Ig Therapy Attenuates Recall Alloantibody Responses in a Mouse Model of HLA Sensitization
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
[bald]Background[/bald] We previously reported that IL-6 inhibition by anti-IL6R antibody (mMR16-1) or CD28 pathway inhibition using CTLA4Ig (abatacept) reduced recall alloantibody responses in a mouse…2015 American Transplant Congress
A Novel, Blocking Anti-CD40 Monoclonal Antibody Prolongs Non-Human Primate Renal Allograft Survival in the Absence of B-Cell Depletion Or Thromboembolic Events
Background. CD40-CD154 pathway blockade prolongs renal allograft survival in non-human primates (NHPs). However, antibodies targeting CD154 were associated with an increased incidence of thromboembolic complications…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- 30
- Next Page »